Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy

  • Authors:
    • Kenji Nakano
    • Yasuyoshi Sato
    • Takashi Toshiyasu
    • Yukiko Sato
    • Lina Inagaki
    • Junichi Tomomatsu
    • Toru Sasaki
    • Wataru Shimbashi
    • Hirofumi Fukushima
    • Hiroyuki Yonekawa
    • Hiroki Mitani
    • Kazuyoshi Kawabata
    • Shunji Takahashi
  • View Affiliations

  • Published online on: November 25, 2015     https://doi.org/10.3892/mco.2015.687
  • Pages: 303-309
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although high‑dose cisplatin is the standard regimen of concurrent chemoradiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (HNSCC), varying levels of patient tolerance towards cisplatin have been reported, and the predictive factors of cisplatin tolerance remain to be elucidated. The present study retrospectively reviewed newly diagnosed HNSCC patients who received CCRT. Cisplatin (80 mg/m2) was administered every 3 weeks. The proportion of high‑dose cisplatin‑tolerant patients (cumulative cisplatin dose, ≥200 mg/m2) was determined, and the predictive factors of cisplatin tolerance were analyzed in a logistic regression analysis. Between June 2006 and March 2013, a total of 159 patients were treated with CCRT. The median follow‑up time was 36.7 months. A total of 73 patients (46%) tolerated a cumulative cisplatin dose ≥200 mg/m2; male gender [odds ratio (OR), 25.00; P=0.005] and high body surface area (BSA) (>1.80 m2; OR, 2.21; P=0.032) were significantly predictive of high‑dose cisplatin tolerance. The high‑dose cisplatin‑tolerant patients had a significantly higher complete response (CR) rate (82 vs. 67%, P=0.045); however, there were no significant between‑group differences in the 3‑year OS (79.5 vs. 81.2%, P=0.59) or PFS (70.4 vs. 44.6%, P=0.076) by cisplatin tolerance. In clinical practice, approximately one‑half of the patients tolerated high‑dose cisplatin in CCRT. Male gender and high BSA could be predictive of cisplatin tolerance.
View Figures
View References

Related Articles

Journal Cover

February 2016
Volume 4 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakano, K., Sato, Y., Toshiyasu, T., Sato, Y., Inagaki, L., Tomomatsu, J. ... Takahashi, S. (2016). Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy. Molecular and Clinical Oncology, 4, 303-309. https://doi.org/10.3892/mco.2015.687
MLA
Nakano, K., Sato, Y., Toshiyasu, T., Sato, Y., Inagaki, L., Tomomatsu, J., Sasaki, T., Shimbashi, W., Fukushima, H., Yonekawa, H., Mitani, H., Kawabata, K., Takahashi, S."Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy". Molecular and Clinical Oncology 4.2 (2016): 303-309.
Chicago
Nakano, K., Sato, Y., Toshiyasu, T., Sato, Y., Inagaki, L., Tomomatsu, J., Sasaki, T., Shimbashi, W., Fukushima, H., Yonekawa, H., Mitani, H., Kawabata, K., Takahashi, S."Predictive factors of head and neck squamous cell carcinoma patient tolerance to high‑dose cisplatin in concurrent chemoradiotherapy". Molecular and Clinical Oncology 4, no. 2 (2016): 303-309. https://doi.org/10.3892/mco.2015.687